The approval is supported by strong preclinical data demonstrating MP1032's capacity to sustain muscle function.

The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa ...

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy ...

Preliminary data from clinical trials of tecovirimat as a treatment for mpox virus infection have given disappointing results ...

David King of Samsung Biologics shares insights on market demand and the technologies and capabilities needed to support ...

ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...

CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to tumor cells. When administered with a ...

PTC Therapeutics Inc. will be launching its oral phenylketonuria therapy, Sephience (sepiapterin) in both the U.S. and Europe this summer, following the U.S. FDA approval just ahead of its July 29 ...